Investigators Testing Ways To Overcome Gleevec Resistance: High Dose, New Drugs
FDA Approves Abraxane For Second-Line Treatment Of Metastatic Breast Cancer
New Regimens May Benefit Multiple Myeloma Patients
Two New Modalities Promising For Relapsed/Refractory NHL
Amgen’s Kepivance Approved For Severe Oral Mucositis
Clolar Approved for Pediatric Refractory/Relapsed ALL
Blacks Half As Likely To Get Surgery For Esophageal Cancer
NCI-Approved Clinical Trials Listed For January
Trending Stories
- With five-year cancer survival at an all-time high, does this mean people are living longer?
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- An oncologist navigates terminal sarcoma, insurmountable debt, and “a legacy of grief”
How colleagues and Fargo, ND, neighbors came together to help the Erickson-Abou Zahrs - Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - House passes three-year extension of ACA subsidies with bipartisan support
- When “safe and effective” is not “reasonable and necessary”
We can curb excessive drug dosing and improve the quality of cancer care









